Doximity, Inc. (NASDAQ:DOCS) Receives $29.36 Consensus PT from Analysts

Doximity, Inc. (NASDAQ:DOCSGet Free Report) has been assigned a consensus recommendation of “Hold” from the eleven research firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $28.10.

DOCS has been the subject of several research reports. Morgan Stanley raised their target price on Doximity from $21.00 to $25.00 and gave the company an “underweight” rating in a research note on Friday, November 10th. Barclays initiated coverage on Doximity in a research report on Wednesday, January 3rd. They issued an “equal weight” rating and a $31.00 price target for the company. Piper Sandler increased their price target on Doximity from $21.00 to $23.00 and gave the company a “neutral” rating in a research report on Friday, November 10th. Truist Financial increased their price target on Doximity from $28.00 to $29.00 and gave the company a “hold” rating in a research report on Friday. Finally, Bank of America increased their price target on Doximity from $29.00 to $32.00 and gave the company a “neutral” rating in a research report on Tuesday, January 23rd.

View Our Latest Research Report on DOCS

Insider Transactions at Doximity

In other news, Director Kira Scherer Wampler sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $28.27, for a total transaction of $141,350.00. Following the completion of the sale, the director now directly owns 10,258 shares of the company’s stock, valued at approximately $289,993.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 39.40% of the company’s stock.

Institutional Investors Weigh In On Doximity

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. purchased a new stake in shares of Doximity during the 2nd quarter worth about $27,000. First Horizon Advisors Inc. raised its stake in shares of Doximity by 111.3% in the 4th quarter. First Horizon Advisors Inc. now owns 995 shares of the company’s stock valued at $28,000 after acquiring an additional 524 shares in the last quarter. Quarry LP bought a new position in shares of Doximity in the 1st quarter valued at approximately $38,000. American International Group Inc. bought a new position in shares of Doximity in the 2nd quarter valued at approximately $43,000. Finally, GAMMA Investing LLC bought a new position in shares of Doximity in the 4th quarter valued at approximately $40,000. 54.65% of the stock is owned by hedge funds and other institutional investors.

Doximity Stock Up 6.5 %

Shares of DOCS stock opened at $30.46 on Tuesday. The stock has a 50-day simple moving average of $27.86 and a 200 day simple moving average of $25.09. Doximity has a fifty-two week low of $19.71 and a fifty-two week high of $37.10. The stock has a market capitalization of $5.66 billion, a P/E ratio of 46.14, a P/E/G ratio of 4.78 and a beta of 1.18.

About Doximity

(Get Free Report

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Featured Articles

Analyst Recommendations for Doximity (NASDAQ:DOCS)

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.